TG THERAPEUTICS, INC. financial data

Symbol
TGTX on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 05 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 427% % 0.69%
Quick Ratio 98% % 34%
Debt-to-equity 121% % -17%
Return On Assets 60% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 158,759,451 shares 2%
Common Stock, Shares, Outstanding 155,210,533 shares -0.36%
Entity Public Float $2,500,000,000 USD -26%
Common Stock, Value, Issued $159,000 USD 1.9%
Weighted Average Number of Shares Outstanding, Basic 145,416,901 shares 0.22%
Weighted Average Number of Shares Outstanding, Diluted 160,997,977 shares 0.18%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $531,898,000 USD 101%
Research and Development Expense $142,897,000 USD 63%
Costs and Expenses $429,119,000 USD 62%
Operating Income (Loss) $102,779,000 USD 136%
Nonoperating Income (Expense) $15,029,000 USD -12%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $87,750,000 USD 507%
Income Tax Expense (Benefit) $359,723,000 USD -94169%
Net Income (Loss) Attributable to Parent $447,473,000 USD 9975%
Earnings Per Share, Basic 3 USD/shares 8867%
Earnings Per Share, Diluted 2 USD/shares 12050%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $74,081,000 USD -62%
Cash, Cash Equivalents, and Short-term Investments $178,300,000 USD -48%
Accounts Receivable, after Allowance for Credit Loss, Current $265,384,000 USD 129%
Inventory, Net $146,953,000 USD 74%
Other Assets, Current $55,846,000 USD 71%
Assets, Current $599,765,000 USD 4.5%
Deferred Income Tax Assets, Net $366,627,000 USD
Property, Plant and Equipment, Net $66,000 USD -72%
Operating Lease, Right-of-Use Asset $6,501,000 USD -12%
Goodwill $799,000 USD 0%
Other Assets, Noncurrent $2,045,000 USD -3.3%
Assets $1,025,024,000 USD 75%
Liabilities, Current $156,810,000 USD 25%
Operating Lease, Liability, Noncurrent $7,308,000 USD -13%
Liabilities $417,806,000 USD 6.1%
Retained Earnings (Accumulated Deficit) $1,105,052,000 USD 29%
Stockholders' Equity Attributable to Parent $607,218,000 USD 216%
Liabilities and Equity $1,025,024,000 USD 75%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $28,715,000 USD -250%
Net Cash Provided by (Used in) Financing Activities $6,102,000 USD -161%
Net Cash Provided by (Used in) Investing Activities $12,934,000 USD -40%
Common Stock, Shares Authorized 190,000,000 shares 0%
Common Stock, Shares, Issued 158,754,176 shares 1.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $47,751,000 USD -174%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $75,410,000 USD -62%
Interest Paid, Excluding Capitalized Interest, Operating Activities $6,143,000 USD 151%
Deferred Tax Assets, Valuation Allowance $414,614,000 USD -0.88%
Deferred Tax Assets, Gross $414,614,000 USD -0.88%
Operating Lease, Liability $8,376,000 USD -13%
Payments to Acquire Property, Plant, and Equipment $25,000 USD
Lessee, Operating Lease, Liability, to be Paid $11,055,000 USD -16%
Operating Lease, Liability, Current $1,068,000 USD -13%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,913,000 USD -8%
Lessee, Operating Lease, Liability, to be Paid, Year One $2,080,000 USD -0.95%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2,679,000 USD -25%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,827,000 USD -4.5%
Deferred Tax Assets, Operating Loss Carryforwards $294,046,000 USD -7.2%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,827,000 USD 0%
Operating Lease, Payments $500,000 USD -17%
Additional Paid in Capital $1,812,345,000 USD 3.7%
Depreciation, Depletion and Amortization $8,000 USD -72%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $55,100,000 USD 47%
Interest Expense $12,059,000 USD 16%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%